25 July 2026
In plain English
A quiet day after the storm. Two days ago the FDA's peptide advisory panel voted to let two experimental recovery drugs — BPC-157 and KPV (short protein fragments called peptides) — be custom-made at specialty pharmacies. Fresh reporting now confirms all four drugs reviewed that day got a green light, not just two. That doesn't change anything for us: we already marked our "the panel will say no" bet wrong, and our "at least two get through" bet right. One useful reality check: nothing is actually legal yet. Making these drugs officially available still needs a formal FDA rule that typically takes 8 to 12 months. So the telehealth company everyone's excited about, Hims & Hers, has a green light in principle but no legal product to sell today. Separately, we caught a stale date on our own pet site and are fixing it.
Signal detail
New this run: Hims CMO Anant Vinjamoori testified at the PCAC hearing in support of reclassification ([Time](https://time.com/article/2026/07/23/fda-committee-peptides/), [Simply Wall St](https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/fda-peptide-shift-and-leadership-change-could-be-a-game-chan)) — intent could not be more explicit. The Skeptic's cap holds equally: multiple sources put Cat 1 legality 8–12 months out via notice-and-comment rulemaking, so a fully compliant BPC-157 line still has no legal footing in 2026. The launch-first-retreat-under-enforcement pattern is exactly why the forecast sits at 0.87 and not higher or lower. Horizon Dec 31.
Convergence-week coverage continues ([TechTimes](https://www.techtimes.com/articles/321365/20260723/gray-market-peptide-users-face-legal-limbo-fda-scientists-oppose-bpc-157-vote.htm) on gray-market "legal limbo"; a Regenexx explainer surfacing endotoxin, heavy-metal and <50%-of-label contamination findings) — but still no top-5 national injury/contamination/deaths feature. 249 days out.
Day 25. A targeted search for early enrollment figures returned only program-structure pages ([CMS](https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge), [AJMC](https://www.ajmc.com/view/medicare-glp-1-bridge-launches-but-who-actually-qualifies-)) — no numbers yet. Near-zero bridge search demand in our GSC; year-one Part D base rates keep sub-1M dominant.
First-party pulse is the tell: Katalys $600 payout / 3 conversions this week (prior $300), 100% GLP-1 (Trim Rx, Embody), zero peptide DTC partners; GSC impressions +57% driven entirely by Embody/tirzepatide queries. The 8–12mo rulemaking delay pushes any compliant peptide affiliate surface past 2026. CPA math structural. New forecast candidate (operator approval required, not auto-added): pet-GLP-1 is a live Ring 1 domain with no forecast attached. Candidate — "Okava reports statistically significant MEOW-1 weight-loss efficacy vs control before 2027-09-30 (draft p≈0.55)." Thin/long-horizon; offered for the coverage log, not urged.
Resolutions & upcoming
- OVERDUE (2 days, awaiting operator write): `bpc157-pcac-2026` → FALSE (Brier 0.49); `pcac-july-multi-peptide` → TRUE (Brier 0.2025). Ra flagged both on 07-24 and re-flags today — the outcome is confirmed and unambiguous; only the manual write to `resolutions.tsv` + `forecasts.tsv` remains. Publishing the miss and the hit on the same event is the brand. - Upcoming (next 14 days): none resolve. Next horizons all Dec 31 2026 (`medicare-glp1-bridge-uptake`, `hims-peptide-launch`, `peptide-affiliate-share`), then `peptide-safety-incident` on Mar 31 2027.
How Barque got smarter today
- "Recommended" ≠ "legal." The single most actionable correction this run is the 8–12-month rulemaking gap between a PCAC yes and lawful compounding. It's the load-bearing assumption under both `hims-peptide-launch` (why 0.87, not 0.95) and `peptide-affiliate-share` (why the >30% flip stays remote in 2026). Worth stating as a standing heuristic: a favorable advisory vote moves narrative and stock price immediately but legal supply on a rulemaking lag — price the two on different clocks.
- Ra caught its own portfolio drift. The MEOW-1 timeline correction (summer 2026 → summer 2027) came from cross-checking a fresh press cycle against a two-month-old work-order, not from any firehose match. Re-reading our own shipped content against new dates is a cheap, repeatable audit — the readout-watch ribbon would otherwise have implied imminent data for another year.
- Post-event confirmation still pays. Waiting one extra cycle resolved the TB-500/MOTs-C reporting inconsistency (all four passed) at zero probability cost — the forecasts were already at the floor/ceiling. Cheap certainty for the resolution record.